BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

18 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery and Optimization of 1-Phenoxy-2-aminoindanes as Potent, Selective, and Orally Bioavailable Inhibitors of the NaEBI
Sanofi-Aventis Deutschland
G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges.EBI
Sanofi-Aventis Deutschland
Benzimidazole-carboxamides as potent and bioavailable stearoyl-CoA desaturase (SCD1) inhibitors from ligand-based virtual screening and chemical optimization.EBI
Sanofi-Aventis Deutschland
Identification of high-affinity P2Y12 antagonists based on a phenylpyrazole glutamic acid piperazine backbone.EBI
Sanofi-Aventis Deutschland
Novelß-amino acid derivatives as inhibitors of cathepsin A.EBI
Sanofi-Aventis Deutschland
Selective non-lipid modulator of LPA5 activity in human platelets.EBI
Sanofi-Aventis Deutschland
Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds.EBI
Sanofi-Aventis Deutschland
Identification and synthesis of novel inhibitors of acetyl-CoA carboxylase with in vitro and in vivo efficacy on fat oxidation.EBI
Sanofi-Aventis Deutschland
Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based renin inhibitors.EBI
Sanofi-Aventis Deutschland
Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening.EBI
Sanofi-Aventis Deutschland
Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes.EBI
Sanofi-Aventis Deutschland
Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).EBI
Sanofi-Aventis Deutschland
CROSS: an efficient workflow for reaction-driven rescaffolding and side-chain optimization using robust chemical reactions and available reagents.EBI
Sanofi-Aventis Deutschland
Characterizing hydration sites in protein-ligand complexes towards the design of novel ligands.EBI
Sanofi-Aventis Deutschland
Novel nicotinamide analog as inhibitor of nicotinamide N-methyltransferase.EBI
Sanofi-Aventis Deutschland
Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations.EBI
Sanofi-Aventis Deutschland
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.EBI
Sanofi-Aventis Deutschland